Wire · operational-macro
FDA Grants Traditional Approval to Pembrolizumab for TMB-H Solid Tumors
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 October 2026 · Fusion42 review
The FDA granted traditional approval to pembrolizumab for treating adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors, amending the TMB-H threshold from ≥10 to ≥13 mutations per megabase based on confirmed efficacy.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
Your drug development plan for immunotherapy now faces a higher biomarker threshold that tightens patient eligibility but increases the pathway's certainty in the US. Expect competition to shift toward predictive test precision and long-term response data for TMB-H approvals.
◆ Coverage
2 sources · 22 Oct 2026
◆ Related on Wire
◆ Topics